Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Safety, Tolerability, and Pharmacokinetic Phase I Clinical Study of Naoqingzhiming Tablets in Chinese Healthy Subjects

NCT04902534 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.

NCT NCT04902534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04902534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Safety, Tolerability, and Pharmacokinetic Phase I Clinical Study of Naoqingzhiming Tablets in Chinese Healthy Subjects
Lead sponsor
The Affiliated Hospital of Qingdao University
Phase
Phase 1
Overall status
Unknown status
Start date
August 5, 2020
Completion date
June 25, 2021
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers